CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA
Abstract
Authors
AJ Palmer L Annemans S Roze M Lamotte P Lapuerta S Gabriel R Chen P Carita I Villadary R Rodby D de Zeeuw HH Parving